Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
- Conditions
- -dopa induced dyskinesias in patients with Parkinson?s diseaseMedDRA version: 14.0Level: HLTClassification code 10013929Term: Dyskinesias and movement disorders NECSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- EUCTR2011-002073-30-ES
- Lead Sponsor
- ovartis Farmaceutica, S.A.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 63
? Outpatients with Parkinson's disease (PD), treated with L-Dopa, experiencing dyskinesias for at least three months
? Outpatients who are on a stable anti-parkinsonian treatment regimen for at least four weeks
Other protocol-defined inclusion criteria may apply
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 33
? Surgical treatment for PD
? Cancer within the past 5 years (other than localized skin cancer and prostate cancer that has been effectively treated)
? Advanced, severe or unstable disease (other than PD) or evidence of dementia that may interfere with the study outcome evaluations
Other protocol-defined exclusion criteria may apply
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method